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Age at Prior Response CurrentPt # diagnosis Marrow Treatment to CLO Status1 11 11q23 1-Ara-C/
Dauno/
6-TG (induction
failure)CR (2) Died with
fungal sepsis2 8 11q23 1-Ara-C/
Dauno/VP/
L-ASP (CR-1)CR (1) CR continues
after 7 cycles
of CLO but
has chronic
thrombocytopenia3 13 t(8;21) 1-Ara-C/
Dauno/etoposide/
IT1Ara-C/
Mito (CR-1)CR (1) In CR,
undergoing BMT4 4 Monosomy 7 1-Ara-C/VP/
Dauno/
etoposide
(CR-1)CR (1) Relapsed after
2nd BMT,
undergoing
induction
with CLO5 10 Monosomy
5, 181-Ara-C/
etoposide/
6-TG/Dauno/
gemtuzumab/
Mito/IT 1
Ara-C (PR)No response
(1)Died of
progressive disease
and toxicities
following
BMT6 1.5 Noninformative 1-Ara-C/
Dauno/
etoposide/
6-TG/Mito/No response
(1)Died of
progressive
diseaseCLO: clofarabine; Ara-C: cytarabine; Dauno: daunorubicin; 6-TG: 6-thi-
oguanine; CR: complete remission; VP: etoposide1 cisplatin; L-ASP: L-
asparaginase; IT: ifosfamide1 paclitaxel; Mito: mitoxantrone; PR: partial
response.LYMPHOMA/MULTIPLE MYELOMA
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FUSION CELL VACCINATION IN CONJUNCTION WITH STEM CELL TRANS-
PLANTATION IS WELL TOLERATED, INDUCES ANTI-TUMOR IMMUNITY
AND IS ASSOCIATED WITH RESPONSES IN PATIENTS WITH MULTIPLE
MYELOMA
Avigan, D.1, Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bissonnette, A.2,
Somaiya, P.1, MacNamara, C.1, Uhl, L.1, Avivi, I.3, Katz, T.3,
Zarwan, C.1, Joyce, R.1, Levine, J.D.1, Lowe, K.1, Dombagoda, D.1,
Tzachanis, D.1, Boussiotis, V.1, Giallombardo, N.1, Mortellite, J.1,
Conway, K.1, Fitzgerald, D.1, Richardson, P.2, Anderson, K.2,
Munshi, N.2, Rowe, J.3, Tsumer,M.3, Bishart, L.3, Kufe, D.2 1Beth Israel
Deaconess Medical Center, Boston, MA; 2Dana Farber Cancer Institute,
Boston, MA; 3Rambam Medical Center, Haifa, Israel
Autologous transplantation results in improved outcomes in pa-
tients with multiple myeloma (MM), but patients relapse from
persistent disease. A promising area of investigation is the develop-
ment of cancer vaccines that educate host immunity to target mye-
loma cells. We have developed a cancer vaccine in which DCs are
fused to autologous MM cells. We are conducting a study in which
patients with MM undergo stem cell transplantation followed by
post-transplant vaccination with DC/MM fusions. DCs were gener-
ated from adherent mononuclear cells cultured with GM-CSF and
IL-4 and TNFa. Myeloma cells were isolated from bone marrow as-
pirates. DC and MM cells were fused with polyethylene glycol. To
date, 26 patients have been enrolled. Mean yield of the DC and my-
eloma preparations was 171  106 and 70  106 cells, respectively.
Mean fusion efficiency was 40% and the mean cell dose generated
was 4 106 fusion cells. As ameasure of their potency as antigen pre-
senting cells, fusion cells potently stimulated allogeneic T cell pro-
liferation in vitro. Mean stimulation indexes were 12, 57, 31 for T
cells stimulated by MM cells, DCs, and fusions. Adverse events
were mild. 14 patients have completed vaccinations of which 8have achieved a complete remission and 6 a partial remission. Of
note, 4 patients achieved complete remission only with vaccination.
T cell responses to PHA and tetanus toxoid were depressed post-
transplant. In contrast, a significant increase was noted post-trans-
plant in circulating tumor reactive lymphocytes as determined by
T cell expression of IFNg following ex vivo exposure to autologous
myeloma cell lysate (Mean percentage of tumor reactive CD8 cells
was 0.9 and 11 pre and post-transplant, respectively p 5 0.01;
mean percentage of CD4 cells was 0.7 and 2.7; p 5 0.02). A further
amplification of tumor reactive lymphocytes was seen with vaccina-
tion (mean percentage of CD4 and CD8 tumor reactive T cells was
4.9 and 15, respectively). A decrease in circulating regulatory T cells
was observed following transplantation. In summary, fusion cell
vaccination in conjunction with stem cell transplantation was well
tolerated, induced anti-tumor immunity and clinical responses.
The post-transplant period is characterized by decreased levels of
regulatory T cells and enhanced levels of tumor reactive T cells.
The increase in tumor reactive T cells post-transplant is further
amplified following vaccination with DC/MM fusion cells.175
PRODUCTION OF MAGE-A4-SPECIFIC CTL FROM HEALTHY DONORS,
PATIENTS, AND CORD BLOOD FOR LYMPHOMA THERAPY AFTER TRANS-
PLANT
Cruz, C.R.Y.1, Leen, A.M.1, Shafer, J.A.1, Younes, A.2, Rooney, C.M.1,
Gerdemann, U.1, Christin, A.S.1, Heslop, H.E.1, Bollard, C.M.1 1Baylor
College of Medicine, Houston, TX; 2MD Anderson Cancer Center,
Houston, TX
Patientswho relapsewithHodgkin’s Lymphoma (HL) – often pre-
senting with chemo- and radio- resistant disease – may benefit from
immunotherapeutic strategies as adjuvant or salvage therapy after he-
matopoietic stem cell transplantation (HSCT). We have previously
demonstrated that infusion of cytotoxic T cells directed against Ep-
stein Barr virus (EBV)-derived proteins expressed in tumors induced
complete remissions in patients with relapsed EBV-positive HL.
However, approximately 70% of relapsed lymphomas are EBV-
negative. Therefore, we investigated the use of another immunother-
apeutic target, the cancer/testis antigen MAGE-A4, which is
frequently expressed by Hodgkin Reed Sternberg cells. The re-
stricted expression of this protein in immune-privileged germ cells
andmalignant cells makes it an attractive target for the ex vivo gener-
ation of tumor-specific T cells. Using dendritic cells pulsed with an
overlapping peptide library spanning the entire MAGE A4 protein
as antigen presenting cells, and culturing responder T cells in the
presence of the cytokines IL7, IL12, and IL15, we have successfully
expandedMAGE-A4-specificT cells fromdifferent sources of hema-
topoietic stem cells: patients with Hodgkin’s Lymphoma (n 5 3),
healthy donors (n 5 5), and umbilical cord blood (n 5 1). After 2
weeks expansion, 4of 8CTL lines contained ameanof 62.62%(range
49.55 – 79.86%) CD81 and 11.41% (range 1.64 – 17.88%) CD41
T-cells. ELISPOT assays on CTL lines demonstrated a mean of
147.54 (range 29–716) IFNg-producing cells (IPC)/1 10e5T-cells
following incubation with MAGE A4 peptides. No significant re-
sponse to irrelevant peptides was demonstrated (mean 9.14; range
2–21.5 IPC/10e5 cells). Peptide pool mapping allowed us to identify
a single, previously uncharacterized epitope (aa266–285, the NPAR-
YEFLWGPRALAETSYV peptide) in the majority of healthy do-
nors. Additional analysis on an evaluable CTL line showed that the
response to the NPA peptide was mediated by CD81T cells, which
demonstrated cytotoxic activity against peptide-pulsed autologous
targets using the Cr51 release assay. These early results suggest that
adoptive immunotherapy utilizing allogeneic, autologous or umbili-
cal cord blood as sources of T cells is a promising approach for the
treatment of relapsed HL after stem cell transplant.176
BORTEZOMIB TARGETS STROMA-MEDIATED APO2L/TRAIL APOPTOSIS
RESISTANCE IN MULTIPLE MYELOMA
Perez, L.E.1, Parquet, N.1, Anasetti, C.1, Dalton, W.2 1H Lee Moffitt
Cancer Center & Research Institute, Tampa, FL; 2H Lee Moffitt Cancer
Center & Research Institute, Tampa, FL
APO2L/TRAIL mediates graft versus tumor (GVT) responses
while sparing normal tissues. We have shown that stroma promotes
66 Poster Session-Iresistance to immune control by APO2L/TRAIL in myeloma cells
by increasing synthesis of the anti-apoptotic protein c-FLIP, process
referred as environmental mediated-immune resistance (EM-IR) (J
Immunol, 180: 3; 2008). In this study we tested the hypothesis that
bortezomib may reverse APO2L/TRAIL EM-IR through its effects
on APO2L/TRAIL signaling pathways and/or related to modifica-
tions of stroma induced signals. To this end RPMI 8226 and U266
MM cells were treated adhered to HS5 stroma or exposed to HS5
in a transwell system. Pretreatment with bortezomib (10nM for 20
hours) not only induced synergistic cytotoxicity in myeloma but
did overcome TRAIL (10mg/mL for 4 hours) apoptosis resistance
induced by HS5 adhesion or HS5-released soluble factors. Mecha-
nistic studies showed that bortezomib is not cytotoxic to HS5 and
does not alter HS5 release of IL-6. Cytokine array testing showed
that stroma-myeloma co-culture lead to a significant increase in
IL-10 but bortezomib had no effect on IL-10 or other cytokines.
Bortezomib increased expression of TRAIL receptors (DR5,
DCR1 and DCR2), but such expression per se did not predict for
sensitivity to apoptosis. Factors released by HS5 stroma increased
expression of c-FLIP in myeloma cells, and bortezomib effectively
reduced c-FLIP. To determine whether the protection mediated
by stroma was directly linked to its ability to induce NF-kB, we
studied the activation of the transcription factor by a gel shift assay.
Bortezomib decreased NF-kB activation in MM without stroma but
was less effective in blocking it activation in the presence of stroma.
Because bortezomib abrogates cytokine-induce kinase activation
and understanding that c-FLIP may be under control of these
kinases, we next studied IL-6 signaling kinases. HS5-released
factor(s) induced STAT-3 and ERK phosphorylation but not AKT
activation, although bortezomib effects on c-FLIP shown to be inde-
pendent of these pathways. Our findings provide the rationale to
combine bortezomib to APO2L/TRAIL treatment to abrogate the
positive influence of the stroma microenvironment on myeloma
cell survival.177
STEM CELL MOBILIZATION IN PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA FOLLOWING THERAPY WITH LENALIDOMIDE
AND DEXAMETHASONE
Kumar, S., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Dingli, D.,
Miceli, T., Litzow, M.R., Rajkumar, S.V., Gertz, M.A. Mayo Clinic,
Rochester, MN
Background: Lenalidomide based regimens appear to impact the
ability to harvest adequate number of stem cells for transplantation. In
order to identify factors predicting for poormobilization,we studied pa-
tients who underwent an attempt at stem cell mobilization after receiv-
ing lenalidomide and dexamethasone as primary therapy for myeloma.
Methods:We identified sequential patients (pts) who received le-
nalidomide and dexamethasone as initial therapy and then underwent
stem cell mobilization. Pts who received any other regimen prior to
the stem cell mobilization were excluded. Between July 2004 and
May 2008, 106 pts, satisfying the above criteria were identified.
Results: The median (range) age at mobilization was 60 yrs (29–
75); 34 (32%) were over 65 yrs. Themedian duration of lenalidomide
therapy was 4 mos (range; 1–13). The strategy for stem cell mobili-
zation was GCSF alone in 92 pts (87%), cyclophosphamide (CTX)
and GCSF in 11 pts and 3 pts received AMD3100 and GCSF.
Among the GCSF mobilized patients, 10 pts (11%) failed to collect
at least 2.5 million cells required for one transplant, including 8 pa-
tients who never achieved the minimum peripheral count threshold
to initiate the collection. Five of these pts subsequently underwent
successful salvage mobilization with CTX/GCSF, 1 with
AMD3100, one failed to mobilize with CTX and the rest did not re-
peat mobilization. Increasing patient age and the duration of lenali-
domide therapy, both correlated with decreasing 2-day CD34
collection, while the time between last dose of lenalidomide and
the start of GCSF had no effect. We then performed ROC analysis
to find best cut-off points that predicted the inability to collect ade-
quate (2.5 million) CD34 cells in 3 days. Lenalidomide therapy of
more than 4 months (P5 0.03) and age.63 yrs (P5 0.04) best pre-
dicted inability to achieve this endpoint. In addition, a peripheral
blood CD34 count\ 5/uL on day 5 after start of GCSF was highly
predictive of failure to reach this endpoint.Conclusions: Inability to collect adequate stem cells appears to be
related to pt age and duration of lenalidomide therapy. Patients
receiving more than 4 cycles of therapy and those over 65 years
should undergo mobilization with CTX1G-CSF, rather than
G-CSF alone. Majority of the pts who fail G-CSF based collection
can bemobilized using CTX andG-CSF. Early identification of fail-
ures using the peripheral CD34 counts can potentially allow salvage
using strategies such as AMD3100.178
TANDEM AUTOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANTATION (HCT) FROM HLA-MATCHED
RELATED OR UNRELATED DONORS FOR ADVANCED LYMPHOMA OR
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Sorror, M.L.1,2, Storer, B.1,2, Sandmaier, B.M.1,2, Chauncey, T.1,2,3,
Storb, R.F.1,2, Maloney, D.G.1,2 1Fred Hutchinson Cancer Research Cen-
ter; 2University of Washington; 3VA Puget Sound Health Care System,
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Thirty-three patients (pts) with advanced non-Hodgkin’s
lymphoma (67%), Hodgkin’s lymphoma (21%), or CLL (12%)
who were ineligible for ablative allogeneic HCT due to age and/or
comorbidities and were thought unlikely to have sustained response
following autograft alone were treated with tandem autologous
HCT followed, after a median of 65 days, by nonmyeloablative con-
ditioning and allograft. Allografts were either from HLA-matched
related (n 5 25) or unrelated donors (n 5 8). Median pt age was 49
years and number of prior regimens was 4 (range 1–12). Thirty-six
percent of pts had disease responsive to the last chemotherapy before
autografting [6% were in complete remission (CR)] while 46% and
18% had refractory and progressive disease, respectively. Most pts
had aggressive disease (82%). Conditioning for autografts consisted
of BEAM (48%) or Cy/12 Gy TBI (52%). At allografting, 52% of
pts hadCR/PR (15%/37%), 12% stable disease, 3% relapse, 33% re-
fractory disease. Nonmyeloablative conditioning for allografts con-
sisted of 2 Gy TBI alone (n 5 21) or with FLU (n 5 12), 90 mg/
m2. Pts received G-CSF mobilized PBMC. After allogeneic HCT,
24 pts became neutropenic for a median of 13 days and 23 pts had
thrombocytopenia (\20,000 cells/ul) for a median of 5 days. All 33
pts had sustained engraftment. Incidences of grades II, III, and IV
acute GVHD were 44%, 19%, and 0% respectively, and chronic
GVHD was 51%. Among 5 pts in CR at HCT, 4 are alive and in
CR and one died in CR. Among 12 in PR at HCT, 6 achieved CR
and are alive, one died in PR, and 5 had progression/relapse (1 is alive
inCR after chemoimmunotherapy andDLI).Of 4 pts with stable dis-
ease at HCT, all are alive, 3 in CR and one in CR after DLI and che-
moimmunotherapy.Among12 ptswith refractory/relapsed disease at
HCT, 5 achieved CR and are alive, 1 died in PR, and 6 relapsed (1 is
alive and inCR for 4 years followingRituximab).Withmedian follow
up of 39 (range 10–87) months, the overall response rate was 63%
(51% CR). Estimated 2-year rates of non-relapse mortality, relapse,
overall, and progression-free survivals from the time of autografting
were 16%, 38%, 55%, and 47% respectively. Histology, disease sta-
tus at autografting or allografting, donor type, conditioning regimens
for autografts, and time between autologous and allogeneic grafting
did not influence outcome. Tandem Auto-Allo HCT resulted in rel-
atively low NRM with median survival not yet reached among pts
with advanced lymphoma/CLL.outcomes by donor type
DonorRelated (n 5 25) Unrelated (n 5 8)% %Acute GVHD, grades II/ III/ IV at 120 days 33/25/0 75/0/0Chronic GVHD 47 63CR 49 572-year NRM 13 252-year progression/relapse 42 252-year PFS 46 502-year OS 57 50
